JP2017532952A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532952A5 JP2017532952A5 JP2017510871A JP2017510871A JP2017532952A5 JP 2017532952 A5 JP2017532952 A5 JP 2017532952A5 JP 2017510871 A JP2017510871 A JP 2017510871A JP 2017510871 A JP2017510871 A JP 2017510871A JP 2017532952 A5 JP2017532952 A5 JP 2017532952A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- seq
- antibody
- antibody agent
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 115
- 239000000203 mixture Substances 0.000 claims description 43
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 33
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 33
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 29
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 229920001184 polypeptide Polymers 0.000 claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 18
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 18
- 235000018102 proteins Nutrition 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 102100038078 CD276 antigen Human genes 0.000 claims description 10
- 241000282326 Felis catus Species 0.000 claims description 10
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims description 10
- 241000282553 Macaca Species 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 208000025174 PANDAS Diseases 0.000 claims description 10
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 claims description 10
- 240000004718 Panda Species 0.000 claims description 10
- 235000016496 Panda oleosa Nutrition 0.000 claims description 10
- 241000282405 Pongo abelii Species 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 241001515942 marmosets Species 0.000 claims description 10
- 241000283073 Equus caballus Species 0.000 claims description 9
- 241000282414 Homo sapiens Species 0.000 claims description 9
- 241000282620 Hylobates sp. Species 0.000 claims description 9
- 241000406668 Loxodonta cyclotis Species 0.000 claims description 9
- 241000282577 Pan troglodytes Species 0.000 claims description 9
- 241000282898 Sus scrofa Species 0.000 claims description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 9
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 9
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 230000010782 T cell mediated cytotoxicity Effects 0.000 claims description 2
- 230000006052 T cell proliferation Effects 0.000 claims description 2
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 238000011467 adoptive cell therapy Methods 0.000 claims description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 2
- 230000003915 cell function Effects 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 239000000562 conjugate Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000006870 function Effects 0.000 claims description 2
- 239000012216 imaging agent Substances 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 229940051026 immunotoxin Drugs 0.000 claims description 2
- 230000002637 immunotoxin Effects 0.000 claims description 2
- 239000002596 immunotoxin Substances 0.000 claims description 2
- 231100000608 immunotoxin Toxicity 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000011363 radioimmunotherapy Methods 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 241000282472 Canis lupus familiaris Species 0.000 claims 5
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 241000283086 Equidae Species 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 241000282596 Hylobatidae Species 0.000 claims 1
- 241000282579 Pan Species 0.000 claims 1
- 241000283080 Proboscidea <mammal> Species 0.000 claims 1
- 241000282887 Suidae Species 0.000 claims 1
- 238000000034 method Methods 0.000 description 43
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 6
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 6
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 6
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 6
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 241000009328 Perro Species 0.000 description 4
- 230000002463 transducing effect Effects 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462042457P | 2014-08-27 | 2014-08-27 | |
| US62/042,457 | 2014-08-27 | ||
| PCT/US2015/047013 WO2016033225A2 (en) | 2014-08-27 | 2015-08-26 | Antibodies, compositions, and uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017532952A JP2017532952A (ja) | 2017-11-09 |
| JP2017532952A5 true JP2017532952A5 (enExample) | 2018-09-27 |
| JP6925264B2 JP6925264B2 (ja) | 2021-08-25 |
Family
ID=55400815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017510871A Active JP6925264B2 (ja) | 2014-08-27 | 2015-08-26 | 抗体、組成物および使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10316093B2 (enExample) |
| EP (1) | EP3186277B1 (enExample) |
| JP (1) | JP6925264B2 (enExample) |
| KR (1) | KR102485788B1 (enExample) |
| CN (1) | CN106715469B (enExample) |
| AU (1) | AU2015306621B2 (enExample) |
| BR (1) | BR112017003582B1 (enExample) |
| CA (1) | CA2959356C (enExample) |
| EA (1) | EA038798B1 (enExample) |
| ES (1) | ES2838750T3 (enExample) |
| WO (1) | WO2016033225A2 (enExample) |
| ZA (1) | ZA201701168B (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9963509B2 (en) * | 2014-12-23 | 2018-05-08 | Full Spectrum Genetics, Inc. | Anti-B7H3 binding compounds and uses thereof |
| US10865245B2 (en) | 2014-12-23 | 2020-12-15 | Full Spectrum Genetics, Inc. | Anti-B7H3 binding compounds and uses thereof |
| CN108025086A (zh) * | 2015-06-23 | 2018-05-11 | 拜耳制药股份公司 | Ksp抑制剂与抗b7h3抗体的抗体-活性物质缀合物(adc) |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| US20190300606A1 (en) * | 2016-07-01 | 2019-10-03 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitory Immune Receptor Inhibition Methods and Compositions |
| WO2018134691A2 (en) | 2017-01-20 | 2018-07-26 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
| WO2018161872A1 (zh) * | 2017-03-06 | 2018-09-13 | 江苏恒瑞医药股份有限公司 | 抗b7-h3抗体、其抗原结合片段及其医药用途 |
| RU2765306C2 (ru) | 2017-03-31 | 2022-01-28 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Антитело против в7-н3, его антигенсвязывающий фрагмент и их медицинское применение |
| CN110770255B (zh) | 2017-04-11 | 2025-07-01 | 因荷布瑞克斯生物科学公司 | 具有受限cd3结合的多特异性多肽构建体及其使用方法 |
| RU2019140833A (ru) * | 2017-05-12 | 2021-06-15 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Применение антител против в7н3 для лечения злокачественных опухолей в центральной нервной системе |
| TW201909926A (zh) * | 2017-08-04 | 2019-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｂ７ｈ３抗體－藥物偶聯物及其醫藥用途 |
| US20200368285A1 (en) | 2017-08-07 | 2020-11-26 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| US11199371B2 (en) | 2017-08-17 | 2021-12-14 | Michael D. Miller | Firearm assembly system and method |
| AU2018328291B2 (en) | 2017-09-08 | 2022-10-27 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| WO2019080883A1 (en) * | 2017-10-26 | 2019-05-02 | Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd. | NOVEL RECOMBINANT FUSION PROTEINS, PREPARATION THEREOF AND USE THEREOF |
| CA3080835A1 (en) | 2017-10-31 | 2019-05-09 | Pantarhei Bioscience B.V. | Immunotherapeutic methods for treating and/or preventing lung cancer |
| CN109939126A (zh) * | 2017-12-21 | 2019-06-28 | 张曼 | Cd3×b7h3双特异抗体定向杀伤耐阿霉素膀胱癌细胞pumc-91/adm的应用 |
| CN109939231A (zh) * | 2017-12-21 | 2019-06-28 | 张曼 | 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞t24的应用 |
| JP7471224B2 (ja) * | 2018-01-15 | 2024-04-19 | シュティッヒティング・サンコン・ブロードフォールジーニング | Ｈ因子増強抗体及びその使用 |
| TWI802633B (zh) | 2018-01-15 | 2023-05-21 | 大陸商南京傳奇生物科技有限公司 | 針對pd-1之單域抗體及其變異體 |
| MX2020010638A (es) | 2018-04-11 | 2021-01-08 | Inhibrx Inc | Constructos de polipeptidos multiespecificos que tienen union a cd3 restringida y metodos y usos relacionados. |
| WO2019225787A1 (ko) | 2018-05-24 | 2019-11-28 | 에이비엘바이오 주식회사 | 항-b7-h3 항체 및 그 용도 |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
| JP7651450B2 (ja) | 2018-07-24 | 2025-03-26 | インヒブルクス バイオサイエンシズ インコーポレイテッド | 制約されたｃｄ３結合ドメインおよび受容体結合領域を含有する多重特異性ポリペプチド構築物ならびにそれを使用する方法 |
| WO2020041626A1 (en) * | 2018-08-23 | 2020-02-27 | The Board Of Trustees Of The Leland Stanford Junior University | Affibody proteins specific for b7-h3 (cd276) |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| JP2022512684A (ja) * | 2018-10-11 | 2022-02-07 | インヒブルクス インコーポレイテッド | Ｂ７ｈ３シングルドメイン抗体およびその治療用組成物 |
| AU2018449846B2 (en) * | 2018-11-22 | 2023-12-14 | Beijing Kanova Biopharmaceutical Co., Ltd. | An anti-B7-H3 antibody |
| JP2022524338A (ja) * | 2019-03-05 | 2022-05-02 | 武田薬品工業株式会社 | 拘束され、条件的に活性化された結合タンパク質 |
| CN109929039A (zh) * | 2019-03-28 | 2019-06-25 | 郑州大学第一附属医院 | 基于cd276抗体的嵌合抗原受体、慢病毒表达载体及其应用 |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| WO2020238926A1 (en) * | 2019-05-28 | 2020-12-03 | Single Cell Technology, Inc. | Anti-b7-h3 antibodies |
| CN114173813A (zh) | 2019-07-03 | 2022-03-11 | 晶体生物科学股份有限公司 | 抗b7-h3抗体及其使用方法 |
| KR102732027B1 (ko) * | 2019-07-09 | 2024-11-20 | 주식회사 와이바이오로직스 | B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도 |
| CA3147638A1 (en) | 2019-07-17 | 2021-01-21 | Gemini Therapeutics Sub, Inc. | Factor h potentiating antibodies and uses thereof |
| WO2021037319A1 (en) | 2019-08-30 | 2021-03-04 | Y-Mabs Therapeutics, Inc. | Immunohistochemical assessment of b7-h3 expression |
| CN110642948B (zh) * | 2019-10-09 | 2021-06-29 | 达石药业(广东)有限公司 | B7-h3纳米抗体、其制备方法及用途 |
| US20230014398A1 (en) * | 2019-11-18 | 2023-01-19 | Board Of Regents, The University Of Texas System | Anti-b7-h3 monoclonal antibody and methods of use thereof |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| EP4138931A1 (en) * | 2020-04-24 | 2023-03-01 | Y-Mabs Therapeutics, Inc. | B7h3 antibodies with chelators |
| US20230312721A1 (en) * | 2020-06-04 | 2023-10-05 | Y-Mabs Therapeutics, Inc. | Anti-B7H3 Antibodies for the Treatment of Cancer |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| EP4172323A1 (en) | 2020-06-29 | 2023-05-03 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| CN112851812B (zh) * | 2020-06-30 | 2021-09-14 | 广州百暨基因科技有限公司 | 抗b7h3抗体及其应用 |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CA3203257A1 (en) * | 2020-12-23 | 2022-06-30 | Li Li | Anti-b7-h3 antibody and uses thereof |
| US20240108745A1 (en) | 2021-02-09 | 2024-04-04 | Medilink Therapeutics (Suzhou) Co., Ltd. | Bioactive substance conjugate, preparation method therefor and use thereof |
| US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| EP4401836A1 (en) * | 2021-09-18 | 2024-07-24 | Skyline Therapeutics Limited | Aav for the gene therapy of wet-amd |
| WO2023060137A2 (en) * | 2021-10-05 | 2023-04-13 | Board Of Regents, The University Of Texas System | Methods and compositions comprising b7-h3 binding polypeptides |
| CN118591563A (zh) * | 2022-01-14 | 2024-09-03 | 盛禾(中国)生物制药有限公司 | 一种结合b7h3和nkp30的双特异性抗体及其应用 |
| US20250144229A1 (en) | 2022-02-16 | 2025-05-08 | Medlink Therapeutics (Suzhou) Co., Ltd. | Conjugate of antibody-eribulin or derivative thereof, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and use thereof |
| CR20240379A (es) | 2022-03-15 | 2024-12-11 | Compugen Ltd | Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia combinada en el tratamiento del cáncer |
| CN116836281A (zh) * | 2022-03-25 | 2023-10-03 | 英诺湖医药(杭州)有限公司 | B7h3抗体及包含其的双功能抗体 |
| JP2025516873A (ja) | 2022-05-18 | 2025-05-30 | ▲蘇▼州宜▲聯▼生物医▲薬▼有限公司 | タンパク質分解剤クラスの生物学的活性化合物を含む抗体薬物複合体及びその調製方法並びに使用 |
| EP4526346A1 (en) * | 2022-05-18 | 2025-03-26 | WuXi Biologics Ireland Limited | Anti-b7h3 antibody and uses thereof |
| CN119768434A (zh) * | 2022-08-19 | 2025-04-04 | 盛禾(中国)生物制药有限公司 | 一种双特异性抗体及其应用 |
| EP4598946A1 (en) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| CN115819608A (zh) * | 2022-10-08 | 2023-03-21 | 盛禾(中国)生物制药有限公司 | 一种纯化融合蛋白的方法 |
| CN115845047A (zh) * | 2022-11-07 | 2023-03-28 | 盛禾(中国)生物制药有限公司 | 一种异源二聚体蛋白质组合物 |
| WO2024106939A1 (ko) * | 2022-11-15 | 2024-05-23 | 주식회사 셀랩메드 | B7-h3에 특이적으로 결합하는 항체 |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
| WO2025129565A1 (zh) * | 2023-12-21 | 2025-06-26 | 西湖实验室(生命科学和生物医学浙江省实验室) | 一种cd276迷你结合蛋白及其突变体及应用 |
| WO2025245264A1 (en) | 2024-05-21 | 2025-11-27 | Briapro Therapeutics Corp. | Anti-b7-h3 antibodies and methods of use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| EP0804070B1 (en) | 1993-03-09 | 2000-05-24 | Genzyme Corporation | Process of isolation of proteins from milk |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US8414892B2 (en) | 2000-10-18 | 2013-04-09 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
| US8501471B2 (en) | 2000-10-18 | 2013-08-06 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
| US7737258B2 (en) * | 2000-10-18 | 2010-06-15 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
| US7666424B2 (en) | 2001-10-17 | 2010-02-23 | Sloan-Kettering Institute For Cancer Research | Methods of preparing and using single chain anti-tumor antibodies |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| CN101687021B (zh) * | 2007-03-22 | 2013-04-17 | 斯隆-凯特琳癌症研究院 | 单克隆抗体8h9的应用 |
| PE20170779A1 (es) * | 2010-03-04 | 2017-07-04 | Macrogenics Inc | Anticuerpos reactivos con b7-h3, fragmentos inmunologicamente activos de los mismos y usos de los mismos |
| AU2011268110B2 (en) | 2010-06-19 | 2016-05-19 | Memorial Sloan-Kettering Cancer Center | Anti-GD2 antibodies |
| US9963509B2 (en) * | 2014-12-23 | 2018-05-08 | Full Spectrum Genetics, Inc. | Anti-B7H3 binding compounds and uses thereof |
-
2015
- 2015-08-26 AU AU2015306621A patent/AU2015306621B2/en active Active
- 2015-08-26 ES ES15835755T patent/ES2838750T3/es active Active
- 2015-08-26 EA EA201790465A patent/EA038798B1/ru unknown
- 2015-08-26 CN CN201580052144.4A patent/CN106715469B/zh active Active
- 2015-08-26 BR BR112017003582-0A patent/BR112017003582B1/pt active IP Right Grant
- 2015-08-26 JP JP2017510871A patent/JP6925264B2/ja active Active
- 2015-08-26 WO PCT/US2015/047013 patent/WO2016033225A2/en not_active Ceased
- 2015-08-26 EP EP15835755.8A patent/EP3186277B1/en active Active
- 2015-08-26 US US15/505,872 patent/US10316093B2/en active Active
- 2015-08-26 KR KR1020177007808A patent/KR102485788B1/ko active Active
- 2015-08-26 CA CA2959356A patent/CA2959356C/en active Active
-
2017
- 2017-02-16 ZA ZA2017/01168A patent/ZA201701168B/en unknown